ReviewFrontiers in microbiology2026
Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- "Lariocidin and ribosome-targeting lasso peptides as emerging antimicrobial agents against multidrug-resistant bacteria".The Journal of antibiotics · 2026Review
- Rethinking Microbial Chemical Ecology: Secondary Metabolites as Concentration-Dependent Signaling Hubs with Implications for Anti-Virulence Intervention.Microorganisms · 2026Review
- Bacterial mutation dynamics emerging insights into virulence evolution and drug resistance. A review study.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accelerating crisis of antimicrobial resistance (AMR) necessitates strategies that extend beyond the continual discovery of new conventional antibiotics. Bacterial secondary metabolites, historically valued as sources of antimicrobial scaffolds, are increasingly recognized for their roles as resistance-modifying and anti-virulence agents. This review synthesizes key advances from 2020 to 2025 that reposition bacterial secondary metabolites as integral components of next-phase AMR intervention strategies. We examine their chemical and biosynthetic diversity, ecological functions, and molecular mechanisms of action, including efflux pump inhibition,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.